根据美国证券交易委员会(SEC)最新披露的文件,生物制药公司Kiora Pharmaceuticals(股票代码:KPRX)计划通过非公开发行的方式,向特定投资者配售438,471股公司普通股。
此次私募配售旨在为公司后续的研发活动及一般营运资金需求筹措资金。该举措反映了公司在资本市场的积极运作,以期支持其长期发展战略。
根据美国证券交易委员会(SEC)最新披露的文件,生物制药公司Kiora Pharmaceuticals(股票代码:KPRX)计划通过非公开发行的方式,向特定投资者配售438,471股公司普通股。
此次私募配售旨在为公司后续的研发活动及一般营运资金需求筹措资金。该举措反映了公司在资本市场的积极运作,以期支持其长期发展战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.